TABLE 3.
Statistics on the therapeutic effect of arsenic trioxide/arsenite combined with TACE.
| Cases of liver cancer | Grouping and treatment method | Objective response rate | Survival rate | Author |
|---|---|---|---|---|
| 62 | Control group: TACE | 15.6% | 46.0% (1 year) | Yan et al. (2013) |
| As2O3 group: As2O3 + TACE | 20.0% | 52.0% (1 year) | ||
| 55 | Control group: TACE | 31.0% | 51.7% (1 year) | Cui et al. (2006) |
| Treatment group: TACE + As2O3 (20 mg/d) | 34.6% | 80.8% (1 year) | ||
| 124 | Control group: TACE | 58.06% | 83.87% (half a year), 45.16% (1 year), and 17.74% (2 years) | Xie et al. (2017) |
| Treatment group: TACE + As2O3 (10 mg/d) | 70.97% | 88.70% (half a year), 62.90% (1 year), and 27.42% (2 years) | ||
| 64 | TACE group | 43.3%。 | 60.0% (1 year), 44.4% (2 years), and 25.0% (3 years) | Qi et al. (2003) |
| TACE + As2O3 group | 73.5% | 88.2% (1 year), 63.3% (2 years), and 42.1% (3 years) | ||
| 82 | Control group: TACE | 53.66% | 60.98% (1 year) and 34.15% (2 years) | Bian et al. (2021) |
| Treatment group: As2O3 (20 mg) + TACE | 75.61% | 82.93% (1 year) and 46.34% (2 years) | ||
| 86 | Control group: TACE | 8.9% | - | Zhou et al. (2007b) |
| As2O3 group: TACE + As2O3(20 mg) | 14.6% | - | ||
| 125 | A group: TACE + As2O3(10 mg/d) | 81.96% | 98.4% (half a year), 93.4% (1 year), and 75.9% (2 years) | Wang et al. (2015) |
| B group: TACE | 59.37% | 87.5% (half a year), 64.1% (1 year), and 50.9% (2 years) | ||
| 80 | Treatment group: As2O3(10 mg) + TACE + Fuzheng Sanjie Decoction | 37.5% | 75% (1 year) | Wan et al. (2021) |
| Control group: As2O3(10 mg) + TACE | 30% | 55% (1 year) | ||
| 30 | TACE + arsenious oxide | 77% | - | Tian et al. (2006) |
| 60 | Control group: As2O3 + TACE | 20.00% | - | Wang et al. (2016) |
| Treatment group: Ganxi tablets + As2O3 + TACE | 26.67% | - |